The Manufacturers Life Insurance Company Purchases New Holdings in Pyxis Oncology, Inc. (NASDAQ:PYXS)

The Manufacturers Life Insurance Company acquired a new position in Pyxis Oncology, Inc. (NASDAQ:PYXS) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 19,730 shares of the company’s stock, valued at approximately $65,000.

Several other large investors also recently bought and sold shares of the company. Fullcircle Wealth LLC acquired a new stake in shares of Pyxis Oncology in the second quarter worth approximately $40,000. SG Americas Securities LLC purchased a new position in Pyxis Oncology in the 1st quarter valued at $59,000. Schulhoff & Co. Inc. boosted its stake in Pyxis Oncology by 90.9% during the 2nd quarter. Schulhoff & Co. Inc. now owns 42,000 shares of the company’s stock worth $139,000 after purchasing an additional 20,000 shares during the last quarter. American Century Companies Inc. grew its holdings in shares of Pyxis Oncology by 56.0% during the second quarter. American Century Companies Inc. now owns 58,252 shares of the company’s stock worth $193,000 after buying an additional 20,901 shares in the last quarter. Finally, Cetera Advisors LLC purchased a new stake in shares of Pyxis Oncology during the first quarter worth $100,000. 39.09% of the stock is currently owned by hedge funds and other institutional investors.

Pyxis Oncology Stock Performance

PYXS opened at $3.68 on Tuesday. The stock has a market capitalization of $216.71 million, a PE ratio of -2.71 and a beta of 1.27. Pyxis Oncology, Inc. has a one year low of $1.35 and a one year high of $6.85. The business’s 50 day moving average price is $3.54 and its 200 day moving average price is $3.75.

Pyxis Oncology (NASDAQ:PYXS) last posted its earnings results on Wednesday, August 14th. The company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. As a group, equities research analysts forecast that Pyxis Oncology, Inc. will post -1.07 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on PYXS shares. Stifel Nicolaus began coverage on shares of Pyxis Oncology in a research report on Thursday, August 8th. They set a “buy” rating and a $10.00 price target on the stock. Royal Bank of Canada restated an “outperform” rating and set a $7.00 target price on shares of Pyxis Oncology in a report on Thursday, September 19th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price target on shares of Pyxis Oncology in a report on Friday, August 16th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $9.00.

Pyxis Oncology Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.